Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts

Pfizer Inc. (NYSE:PFEGet Free Report) has been given an average rating of “Hold” by the seventeen brokerages that are covering the firm, reports. Eleven equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $36.88.

Several research analysts recently issued reports on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Truist Financial cut their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th.

Get Our Latest Analysis on PFE

Institutional Trading of Pfizer

Several hedge funds have recently added to or reduced their stakes in PFE. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter valued at approximately $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer in the 3rd quarter valued at $30,000. Main Street Group LTD purchased a new stake in Pfizer during the 4th quarter valued at $30,000. GoalVest Advisory LLC boosted its position in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Finally, Creekmur Asset Management LLC bought a new position in Pfizer in the 4th quarter worth $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.6 %

PFE opened at $27.55 on Wednesday. Pfizer has a twelve month low of $25.61 and a twelve month high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a fifty day moving average of $27.43 and a 200-day moving average of $29.29. The stock has a market cap of $156.00 billion, a PE ratio of 76.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the company posted $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer will post 2.22 EPS for the current year.

Pfizer Company Profile

(Get Free Report

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.